<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Am J Prev Med</journal-id><journal-id journal-id-type="iso-abbrev">Am J Prev Med</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>American journal of preventive medicine</journal-title></journal-title-group><issn pub-type="ppub">0749-3797</issn><issn pub-type="epub">1873-2607</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10293066</article-id><article-id pub-id-type="pmcid-ver">PMC10293066.319</article-id><article-id pub-id-type="pmcaid">10293066</article-id><article-id pub-id-type="pmcaiid">10293066</article-id><article-id pub-id-type="manuscript-id">NIHMS1870146</article-id><article-id pub-id-type="pmid">36906496</article-id><article-id pub-id-type="doi">10.1016/j.amepre.2023.01.037</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS1870146</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA1870146</article-id><article-version article-version-type="pmc-version">319</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Buprenorphine after non-fatal opioid overdose: Reduced mortality risk in Medicare disability beneficiaries</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Samples</surname><given-names initials="H">Hillary</given-names></name><degrees>PhD, MHS</degrees><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Nowels</surname><given-names initials="M">Molly</given-names></name><degrees>MS, MA</degrees><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Williams</surname><given-names initials="AR">Arthur R.</given-names></name><degrees>MD, MBE</degrees><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Olfson</surname><given-names initials="M">Mark</given-names></name><degrees>MD, MPH</degrees><xref rid="A3" ref-type="aff">3</xref><xref rid="A4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Crystal</surname><given-names initials="S">Stephen</given-names></name><degrees>PhD</degrees><xref rid="A1" ref-type="aff">1</xref><xref rid="A5" ref-type="aff">5</xref></contrib></contrib-group><aff id="A1"><label>1</label>Rutgers Institute for Health, Health Care Policy, and Aging Research, New Brunswick, NJ</aff><aff id="A2"><label>2</label>Department of Health Behavior, Society and Policy, Rutgers School of Public Health, Piscataway, NJ</aff><aff id="A3"><label>3</label>Department of Psychiatry, New York State Psychiatric Institute, Columbia University Medical Center, New York, NY</aff><aff id="A4"><label>4</label>Department of Epidemiology, Columbia University Mailman School of Public Health, New York, NY</aff><aff id="A5"><label>5</label>Rutgers School of Social Work, New Brunswick, NJ</aff><author-notes><corresp id="CR1"><bold>Corresponding Author:</bold> Hillary Samples, PhD, MHS, Center for Pharmacoepidemiology and Treatment Science, Rutgers Institute for Health, Health Care Policy and Aging Research, 112 Paterson St., Room 321 New Brunswick, NJ 08901, <email>h.samples@rutgers.edu</email></corresp></author-notes><pub-date pub-type="ppub"><month>7</month><year>2023</year></pub-date><pub-date pub-type="epub"><day>10</day><month>3</month><year>2023</year></pub-date><volume>65</volume><issue>1</issue><issue-id pub-id-type="pmc-issue-id">439145</issue-id><fpage>19</fpage><lpage>29</lpage><pub-history><event event-type="nihms-submitted"><date><day>03</day><month>02</month><year>2023</year></date></event><event event-type="pmc-release"><date><day>01</day><month>07</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>01</day><month>07</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-09-20 08:25:29.513"><day>20</day><month>09</month><year>2024</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-1870146.pdf"/><abstract id="ABS1"><sec id="S1"><title>Introduction:</title><p id="P1">Opioid-involved overdose mortality is a persistent public health challenge, yet limited evidence exists on the relationship between opioid use disorder (OUD) treatment after non-fatal overdose and subsequent overdose death.</p></sec><sec id="S2"><title>Methods:</title><p id="P2">National Medicare data were used to identify adult (18&#8211;64 years) disability beneficiaries who received inpatient or emergency treatment for non-fatal opioid-involved overdose in 2008&#8211;2016. OUD treatment was defined as: 1) buprenorphine, measured using medication days&#8217; supply, and 2) psychosocial services, measured as 30-day exposures from and including each service date. Opioid-involved overdose fatalities were identified in the year after non-fatal overdose using linked National Death Index data. Cox proportional hazards models estimated associations between time-varying treatment exposures and overdose death. Analyses were conducted in 2022.</p></sec><sec id="S3"><title>Results:</title><p id="P3">The sample (n=81,616) was mostly female (57.3%), 50 years or older (58.8%), and white (80.9%), with a significantly elevated overdose mortality rate compared to the general U.S. population (standardized mortality ratio [SMR]=132.4, 95% CI=129.9, 135.0). Only 6.5% of the sample (n=5329) had OUD treatment after the index overdose. Buprenorphine (n=3774, 4.6%) was associated with significantly lower risk of opioid-involved overdose death (adjusted hazard ratio [aHR]=0.38, 95% CI=0.23, 0.64), but OUD-related psychosocial treatment (n=2405, 2.9%) was not associated with risk of death (aHR=1.18, 95% CI=0.71, 1.95).</p></sec><sec id="S4"><title>Conclusions:</title><p id="P4">Buprenorphine treatment after non-fatal opioid-involved overdose was associated with a 62% reduction in risk of opioid-involved overdose death. However, fewer than 1 in 20 individuals received buprenorphine in the subsequent year, highlighting a need to strengthen care connections following critical opioid-related events, particularly for vulnerable groups.</p></sec></abstract><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>